OS9 Antikörper (AA 101-200) (FITC)

Produktnummer ABIN759558

Produktdetails anti-OS9 Antikörper (FITC)

Target: OS9 (Osteosarcoma Amplified 9, Endoplasmic Reticulum Lectin (OS9))

Bindungsspezifität: AA 101-200

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser OS9 Antikörper ist konjugiert mit FITC

Applikation: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Kreuzreaktivität: Maus

Homologie: Human,Rat,Dog,Cow,Sheep,Horse,Rabbit

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human OS9

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu OS9

Target: OS9 (Osteosarcoma Amplified 9, Endoplasmic Reticulum Lectin (OS9))

Andere Bezeichnung: OS9 (OS9 Produkte)

Synonyme: OS-9 antikoerper, zgc:153838 antikoerper, 4632413K17Rik antikoerper, AU022351 antikoerper, Os-9 antikoerper, ERLEC2 antikoerper, OS9, endoplasmic reticulum lectin antikoerper, osteosarcoma amplified 9, endoplasmic reticulum lectin antikoerper, amplified in osteosarcoma antikoerper, OS9 antikoerper, os9 antikoerper, Os9 antikoerper

Hintergrund:

Synonyms: lied in osteosarcoma 9, amplied in osteosarcoma, OS-9, Os9, OS9_HUMAN, Protein OS-9.

Background: Lectin which functions in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD). May bind terminally misfolded non-glycosylated proteins as well as improperly folded glycoproteins, retain them in the ER, and possibly transfer them to the ubiquitination machinery and promote their degradation. Possible targets include TRPV4.

Gen-ID: 10956

Pathways: Maintenance of Protein Location, SARS-CoV-2 Protein Interaktom